Clinical Trial Information

Actinium Pharmaceuticals, Inc. is committed to improving the lives of patients with cancers that lack effective treatment options.

To learn more about Actinium’s current clinical trials please visit the National Institutes of Health registry database of clinical trials that can be found on the following Web page: www.clinicaltrials.gov. Actinium posts information about its clinical trials such as, a description of the study, patient populations and entry criteria and locations where the trial is being conducted. Please click on the links below to learn about our ongoing clinical trials.

Product Candidate	Study ID	Study Title
Iomab-B	NCT02665065	Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)

If you are a patient, health care proxy, or healthcare professional looking for more information about Actinium’s current or future clinical trials, please email requests related to Iomab-B to iomab@actiniumpharma.com and requests related to Actimab-A to actimab@actiniumpharma.com. An Actinium representative will contact you to provide the requested information.

Bone Marrow Transplant Induction and Conditioning in One

Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. The SIERRA trial completed patient enrollment in the third quarter of 2021. View highlights of Key Opinion Leaders discussing Iomab-B:

View Clinical Panel Discussion

Clinical Trial Information

Bone Marrow Transplant Induction and Conditioning in One

Email Sign Up